Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 8/20 | 0.54 |
| ▸ | FLT3 | P36888 | 7/20 | 0.54 |
| ▸ | KIT | P10721 | 2/20 | 0.54 |
| ▸ | SYK | P43405 | 2/20 | 0.54 |
| ▸ | PLK4 | O00444 | 1/20 | 0.54 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.54 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.54 |
| ▸ | CSF1R | P07333 | 1/20 | 0.54 |
| ▸ | ROS1 | P08922 | 1/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.54 |
| ▸ | SRC | P12931 | 1/20 | 0.54 |
| ▸ | FLT1 | P17948 | 1/20 | 0.54 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.54 |
| ▸ | MARK3 | P27448 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.54 |
| ▸ | CLK2 | P49760 | 1/20 | 0.54 |
| ▸ | GSK3A | P49840 | 1/20 | 0.54 |
| ▸ | GSK3B | P49841 | 1/20 | 0.54 |
| ▸ | PLK1 | P53350 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12509523 | 1.00 | CDK2 (0.54) | CDK2FLT3KITSYKPLK4 | |
| SCHEMBL2196781 | 0.91 | JAK2 (0.56) | CDK2SYKPLK4PRKD3LCK | |
| SCHEMBL12423697 | 0.91 | JAK2 (0.56) | CDK2SYKPLK4PRKD3LCK | |
| SCHEMBL14100332 | 0.89 | CDK2 (0.51) | CDK2FLT3KITSYKPLK4 | |
| SCHEMBL14100347 | 0.87 | CDK2 (0.49) | CDK2FLT3KITSYKPLK4 | |
| SCHEMBL13154245 | 0.87 | JAK2 (0.53) | CDK2FLT3KITSYKPLK4 | |
| SCHEMBL14100244 | 0.86 | CDK2 (0.59) | CDK2FLT3KITSYKPLK4 | |
| SCHEMBL12423691 | 0.86 | IKBKB (0.45) | CDK2FLT3KITSYKPLK4 | |
| SCHEMBL2195856 | 0.86 | IKBKB (0.45) | CDK2FLT3KITSYKPLK4 | |
| SCHEMBL12423387 | 0.84 | CAMK2D (0.48) | CDK2CHEK1GSK3AGSK3BAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977481-B2 | Pyrimidinyl-thiophene kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20100305128-A1 | Pyrimidinyl-Thiophene Kinase Modulators | ARNOLD WILLIAM D | 2010-12-02 | — | — | US | disclosed |
| US-7803806-B2 | Pyrimidinyl-thiophene kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-7803806-B2 | Pyrimidinyl-thiophene kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-20070117800-A1 | PYRIMIDINYL-THIOPHENE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-05-24 | — | — | US | disclosed |
| US-20070117800-A1 | PYRIMIDINYL-THIOPHENE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-05-24 | — | — | US | disclosed |
| WO-2007053776-A1 | PYRIMIDINYL-THIOPHENE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305128-A1 | Pyrimidinyl-Thiophene Kinase Modulators | MAP3K20, MAP3K6, MAP4K2 | CDK2 110/4885FLT3 260/4885KIT 1037/4885 |
| US-20070117800-A1 | PYRIMIDINYL-THIOPHENE KINASE MODULATORS | MAP3K20, MAP3K6, MAP4K2 | CDK2 110/4885FLT3 260/4885KIT 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.